Cytokine biomarkers for the diagnosis of tuberculosis infection and disease in adults in a low prevalence setting.


Journal

Tuberculosis (Edinburgh, Scotland)
ISSN: 1873-281X
Titre abrégé: Tuberculosis (Edinb)
Pays: Scotland
ID NLM: 100971555

Informations de publication

Date de publication:
01 2019
Historique:
received: 24 04 2018
revised: 19 08 2018
accepted: 22 08 2018
entrez: 4 2 2019
pubmed: 4 2 2019
medline: 2 7 2019
Statut: ppublish

Résumé

Accurate and timely diagnosis of tuberculosis (TB) is essential to control the global pandemic. Currently available immunodiagnostic tests cannot discriminate between latent tuberculosis infection (LTBI) and active tuberculosis. This study aimed to determine whether candidate mycobacterial antigen-stimulated cytokine biomarkers can discriminate between TB-uninfected and TB-infected adults, and additionally between LTBI and active TB disease. 193 adults were recruited, and categorised into four unambiguous diagnostic groups: microbiologically-proven active TB, LTBI, sick controls (non-TB lower respiratory tract infections) and healthy controls. Whole blood assays were used to determine mycobacterial antigen (CFP-10, ESAT-6, PPD)-stimulated cytokine (IL-1ra, IL-2, IL-10, IL-13, TNF-α, IFN-γ, IP-10 and MIP-1β) responses, measured by Luminex multiplex immunoassay. The background-corrected mycobacterial antigen-stimulated cytokine responses of all eight cytokines were significantly higher in TB-infected participants compared with TB-uninfected individuals, with IL-2 showing the best performance characteristics. In addition, mycobacterial antigen-stimulated responses with IL-1ra, IL-10 and TNF-α were higher in participants with active TB compared those with LTBI, reaching statistical significance with PPD stimulation, although there was a degree of overlap between the two groups. Mycobacterial antigen-stimulated cytokine responses may prove useful in future immunodiagnostic tests to discriminate between tuberculosis-infected and tuberculosis-uninfected individual, and potentially between LTBI and active tuberculosis.

Identifiants

pubmed: 30711163
pii: S1472-9792(18)30170-7
doi: 10.1016/j.tube.2018.08.011
pii:
doi:

Substances chimiques

Antigens, Bacterial 0
Biomarkers 0
Cytokines 0
Mycobacterium tuberculosis antigens 144058-44-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

91-102

Subventions

Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Vanessa Clifford (V)

Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia; Murdoch Children's Research Institute, Royal Children's Hospital Melbourne, Parkville, VIC 3052, Australia.

Marc Tebruegge (M)

Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia; Murdoch Children's Research Institute, Royal Children's Hospital Melbourne, Parkville, VIC 3052, Australia; Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.

Christel Zufferey (C)

Murdoch Children's Research Institute, Royal Children's Hospital Melbourne, Parkville, VIC 3052, Australia.

Susie Germano (S)

Murdoch Children's Research Institute, Royal Children's Hospital Melbourne, Parkville, VIC 3052, Australia.

Ben Forbes (B)

Murdoch Children's Research Institute, Royal Children's Hospital Melbourne, Parkville, VIC 3052, Australia.

Lucy Cosentino (L)

Victorian Tuberculosis Program, Peter Doherty Institute, Parkville, VIC 3052, Australia.

Elizabeth Matchett (E)

Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, VIC 3052, Australia.

Emma McBryde (E)

Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, VIC 3052, Australia.

Damon Eisen (D)

Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, VIC 3052, Australia.

Roy Robins-Browne (R)

Murdoch Children's Research Institute, Royal Children's Hospital Melbourne, Parkville, VIC 3052, Australia; Department of Microbiology and Immunology, University of Melbourne, VIC 3052, Australia.

Alan Street (A)

Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, VIC 3052, Australia.

Justin Denholm (J)

Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, VIC 3052, Australia; Department of Microbiology and Immunology, University of Melbourne, VIC 3052, Australia; Victorian Tuberculosis Program, Peter Doherty Institute, Parkville, VIC 3052, Australia.

Nigel Curtis (N)

Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia; Murdoch Children's Research Institute, Royal Children's Hospital Melbourne, Parkville, VIC 3052, Australia. Electronic address: nigel.curtis@rch.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH